New Treatment Options Featured in NCCN Antiemesis Guidelines

JENKINTOWN, PA, April 7, 2004 – On March 11, 2004, the National Comprehensive Cancer Network (NCCN), an alliance of nineteen of the world’s leading cancer centers, announced a major update of the NCCN Antiemesis Clinical Practice Guidelines. The NCCN Antiemesis panel recently updated its guidelines for preventing chemotherapy-induced nausea and vomiting to add the 5-HT3 receptor antagonist palonosetron (Aloxi, MGI Pharma Inc.) to multiagent antiemetic regimens for use with highly and moder...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news